- Home
- MMLP vs MGNX Comparison
MMLP vs MGNX Comparison
Compare MMLP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMLP
- MGNX
- Stock Information
- Founded
- MMLP 2002
- MGNX 2000
- Country
- MMLP United States
- MGNX United States
- Employees
- MMLP N/A
- MGNX N/A
- Industry
- MMLP Oil Refining/Marketing
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MMLP Energy
- MGNX Health Care
- Exchange
- MMLP Nasdaq
- MGNX Nasdaq
- Market Cap
- MMLP 139.6M
- MGNX 125.2M
- IPO Year
- MMLP 2002
- MGNX 2013
- Fundamental
- Price
- MMLP $3.60
- MGNX $1.27
- Analyst Decision
- MMLP
- MGNX Hold
- Analyst Count
- MMLP 0
- MGNX 10
- Target Price
- MMLP N/A
- MGNX $6.83
- AVG Volume (30 Days)
- MMLP 117.0K
- MGNX 691.0K
- Earning Date
- MMLP 04-16-2025
- MGNX 03-20-2025
- Dividend Yield
- MMLP 0.57%
- MGNX N/A
- EPS Growth
- MMLP N/A
- MGNX N/A
- EPS
- MMLP N/A
- MGNX N/A
- Revenue
- MMLP $707,622,000.00
- MGNX $149,962,000.00
- Revenue This Year
- MMLP $4.19
- MGNX N/A
- Revenue Next Year
- MMLP N/A
- MGNX $42.52
- P/E Ratio
- MMLP N/A
- MGNX N/A
- Revenue Growth
- MMLP N/A
- MGNX 155.26
- 52 Week Low
- MMLP $2.36
- MGNX $1.17
- 52 Week High
- MMLP $4.13
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- MMLP 45.38
- MGNX 19.69
- Support Level
- MMLP $3.44
- MGNX $1.89
- Resistance Level
- MMLP $3.74
- MGNX $2.24
- Average True Range (ATR)
- MMLP 0.19
- MGNX 0.17
- MACD
- MMLP -0.02
- MGNX -0.08
- Stochastic Oscillator
- MMLP 34.78
- MGNX 7.60
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).